The interleukin-8 receptor: a potential target for antipsoriatic therapy?

Eur J Pharmacol. 1994 Jun 13;258(3):269-72. doi: 10.1016/0014-2999(94)90490-1.

Abstract

Interleukin-8 is assumed to play a central role in the pathogenesis of psoriasis. Since an increased expression of the interleukin-8 receptor has been observed both in polymorphonuclear leukocytes and in affected psoriatic epidermis, we were interested in whether the interleukin-8 receptor could be a molecular target of antipsoriatic compounds. Cyclosporine, calcitriol, calcipotriol or dithranol caused a dose-dependent decrease in interleukin-8 binding to cultured human keratinocytes, while interleukin-8 binding to granulocytes was not affected. In addition, the interleukin-8-induced human leukocyte antigen-DR (HLA-DR) expression of keratinocytes was nearly completely blocked by treatment of the cells with these substances. The inhibition of the keratinocyte interleukin-8 receptor and its function by antipsoriatic drugs may contribute to their therapeutic action.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthralin / pharmacology
  • Calcitriol / analogs & derivatives
  • Calcitriol / pharmacology
  • Cells, Cultured
  • Cyclosporine / pharmacology
  • Flow Cytometry
  • HLA-DR Antigens / biosynthesis
  • Humans
  • Interleukin-8 / metabolism*
  • Keratinocytes / drug effects*
  • Keratinocytes / metabolism
  • Neutrophils / metabolism
  • Psoriasis / drug therapy*
  • Receptors, Interleukin / drug effects*
  • Receptors, Interleukin-8A
  • Recombinant Proteins / pharmacology

Substances

  • HLA-DR Antigens
  • Interleukin-8
  • Receptors, Interleukin
  • Receptors, Interleukin-8A
  • Recombinant Proteins
  • calcipotriene
  • Cyclosporine
  • Calcitriol
  • Anthralin